CO2019011604A2 - Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos - Google Patents
Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismosInfo
- Publication number
- CO2019011604A2 CO2019011604A2 CO2019011604A CO2019011604A CO2019011604A2 CO 2019011604 A2 CO2019011604 A2 CO 2019011604A2 CO 2019011604 A CO2019011604 A CO 2019011604A CO 2019011604 A CO2019011604 A CO 2019011604A CO 2019011604 A2 CO2019011604 A2 CO 2019011604A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods relating
- compositions
- compounds
- inhibitor compounds
- vmat2 inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se proporciona un compuesto seleccionado de compuestos de fórmula (I) y sales, solvatos e hidratos farmacéuticamente aceptables de los mismos: (I) en la que R1, R2, R3 y R4 son tal como se definen en el presente documento. Tales compuestos son inhibidores del transportador vesicular de monoaminas 2 (VMAT2) y tienen utilidad para tratar, por ejemplo, enfermedades y trastornos neurológicos y psiquiátricos. También se dan a conocer composiciones que contienen tales compuestos en combinación con un portador farmacéuticamente aceptable, así como métodos relativos a su uso en sujetos que lo necesitan.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762487413P | 2017-04-19 | 2017-04-19 | |
| US201862652837P | 2018-04-04 | 2018-04-04 | |
| PCT/US2018/028031 WO2018195121A1 (en) | 2017-04-19 | 2018-04-17 | Vmat2 inhibitor compounds and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019011604A2 true CO2019011604A2 (es) | 2019-10-31 |
Family
ID=62111264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO2019011604A CO2019011604A2 (es) | 2017-04-19 | 2019-10-18 | Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11040970B2 (es) |
| EP (1) | EP3612532B1 (es) |
| JP (1) | JP7170662B2 (es) |
| KR (1) | KR20190140968A (es) |
| CN (1) | CN110770236B (es) |
| AU (1) | AU2018254429A1 (es) |
| BR (1) | BR112019021853A2 (es) |
| CA (1) | CA3060251A1 (es) |
| CL (1) | CL2019002919A1 (es) |
| CO (1) | CO2019011604A2 (es) |
| JO (1) | JOP20190239A1 (es) |
| MA (1) | MA50145A (es) |
| MX (1) | MX2019012336A (es) |
| PE (1) | PE20191784A1 (es) |
| TW (1) | TW201841913A (es) |
| WO (1) | WO2018195121A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019008855A (es) | 2017-01-27 | 2019-09-11 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores del transportador de monamina vesicular 2 (vmat2). |
| EP3684333A2 (en) | 2017-09-21 | 2020-07-29 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| MX2020003421A (es) | 2017-10-10 | 2020-07-20 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| MA52896A (fr) * | 2018-06-14 | 2021-04-21 | Neurocrine Biosciences Inc | Composés inhibiteurs de vmat2, compositions et méthodes associées |
| BR112021000019A2 (pt) | 2018-08-15 | 2021-04-06 | Neurocrine Biosciences Inc. | Métodos para administração de certos inibidores de vmat2 |
| WO2020086765A1 (en) * | 2018-10-24 | 2020-04-30 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
| AR125188A1 (es) | 2021-03-22 | 2023-06-21 | Neurocrine Biosciences Inc | Inhibidores del vmat2 y métodos de uso |
| WO2022232380A1 (en) | 2021-04-29 | 2022-11-03 | Neurocrine Biosciences, Inc. | Processes for preparing a vmat2 inhibitor |
| TW202322816A (zh) | 2021-08-20 | 2023-06-16 | 美商紐羅克里生物科學有限公司 | 篩選 vmat2 抑制劑之方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| MXPA05013734A (es) | 2003-06-20 | 2006-03-08 | Hoffmann La Roche | Hexahidropiroisoquinolinas como inhibidores de dpp-iv. |
| JP2008509925A (ja) | 2004-08-13 | 2008-04-03 | オメロス コーポレイション | 新規のセロトニンレセプターリガンドおよびそれらの使用 |
| BRPI0718247B1 (pt) * | 2006-11-08 | 2021-09-21 | Neurocrine Biosciences, Inc. | Composto usado como inibidor do transportador de monoamina vesicular 2, composição farmacêutica compreendendo o dito composto e uso da dita composição farmacêutica no tratamento de transtornos hipercinéticos |
| FR2912145B1 (fr) | 2007-02-02 | 2009-03-06 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US9012471B2 (en) | 2008-04-11 | 2015-04-21 | The Trustees Of Columbia University In The City Of New York | Glucose metabolism modulating compounds |
| CN102186848B (zh) | 2008-09-18 | 2014-11-12 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的苯并喹啉抑制剂 |
| CA2784830C (en) | 2009-12-18 | 2018-03-27 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CN102285984B (zh) | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| US9434741B2 (en) | 2012-09-19 | 2016-09-06 | Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences | Thieno[2,3-d]pyrimidine derivatives, preparation method and use thereof |
| EP4049681A1 (en) | 2014-02-07 | 2022-08-31 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| WO2016127133A1 (en) * | 2015-02-06 | 2016-08-11 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| HUE060233T2 (hu) | 2016-12-22 | 2023-02-28 | Incyte Corp | Tetrahidro imidazo[4,5-c]piridin-származékok mint a PD-L1 internalizációját indukáló szerek |
| MY197635A (en) | 2016-12-22 | 2023-06-29 | Incyte Corp | Benzooxazole derivatives as immunomodulators |
-
2017
- 2017-06-16 JO JOP/2019/0239A patent/JOP20190239A1/ar unknown
-
2018
- 2018-04-17 CA CA3060251A patent/CA3060251A1/en active Pending
- 2018-04-17 TW TW107112964A patent/TW201841913A/zh unknown
- 2018-04-17 EP EP18722357.3A patent/EP3612532B1/en active Active
- 2018-04-17 US US16/606,191 patent/US11040970B2/en active Active
- 2018-04-17 CN CN201880040884.XA patent/CN110770236B/zh active Active
- 2018-04-17 MX MX2019012336A patent/MX2019012336A/es unknown
- 2018-04-17 MA MA050145A patent/MA50145A/fr unknown
- 2018-04-17 BR BR112019021853-0A patent/BR112019021853A2/pt not_active Application Discontinuation
- 2018-04-17 PE PE2019002077A patent/PE20191784A1/es unknown
- 2018-04-17 JP JP2019556587A patent/JP7170662B2/ja active Active
- 2018-04-17 WO PCT/US2018/028031 patent/WO2018195121A1/en unknown
- 2018-04-17 KR KR1020197033620A patent/KR20190140968A/ko unknown
- 2018-04-17 AU AU2018254429A patent/AU2018254429A1/en not_active Abandoned
-
2019
- 2019-10-14 CL CL2019002919A patent/CL2019002919A1/es unknown
- 2019-10-18 CO CO2019011604A patent/CO2019011604A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018195121A1 (en) | 2018-10-25 |
| CN110770236A (zh) | 2020-02-07 |
| CL2019002919A1 (es) | 2020-01-17 |
| TW201841913A (zh) | 2018-12-01 |
| CN110770236B (zh) | 2023-03-24 |
| EP3612532B1 (en) | 2023-12-13 |
| AU2018254429A1 (en) | 2019-11-07 |
| JP2020517607A (ja) | 2020-06-18 |
| US11040970B2 (en) | 2021-06-22 |
| PE20191784A1 (es) | 2019-12-24 |
| MA50145A (fr) | 2020-07-29 |
| KR20190140968A (ko) | 2019-12-20 |
| JP7170662B2 (ja) | 2022-11-14 |
| EP3612532A1 (en) | 2020-02-26 |
| JOP20190239A1 (ar) | 2019-10-09 |
| EP3612532C0 (en) | 2023-12-13 |
| MX2019012336A (es) | 2020-07-14 |
| CA3060251A1 (en) | 2018-10-25 |
| US20200131173A1 (en) | 2020-04-30 |
| BR112019021853A2 (pt) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019011604A2 (es) | Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos | |
| CO2017009891A2 (es) | Inhibidores de inhibidores del factor beta de crecimiento de transformación (tgf-beta) | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| NZ733899A (en) | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| MY177574A (en) | New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
| ECSP10010415A (es) | Compuestos novedosos que son inhibidores de erk | |
| CO2019003482A2 (es) | Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| CO6700838A2 (es) | Compuestos sustituidos de banzamida | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos | |
| ECSP109958A (es) | Derivados de pirimidina 934 | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| ECSP21011232A (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
| NI200900181A (es) | Nuevos compuestos heterocíclicos nitrogenados, su preparación y su utilización como medicamentos antibacterianos. | |
| UY37764A (es) | Nuevos compuestos inhibidores de la prostaglandina d sintasa hematopoyética (h-pgds) | |
| AR117835A1 (es) | Complejo diastereoisomérico enriquecido de gadolinio y de un ligando quelante a base de pcta, y proceso de preparación y purificación del mismo | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| PE20171348A1 (es) | Compuestos de benzoxaborol 4-sustituidos y uso de los mismos | |
| CO6241116A2 (es) | Pirimidil piperazinas utiles como ligandos del receptor d3/d2 | |
| CO2020016080A2 (es) | Compuestos | |
| ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| CO2017011511A2 (es) | Derivados de indol |